Full text loading...
薬理と治療
Abstract
Objective To compare the effects of candesartan and valsartan on endothelial functionassessed by measurement of flow−mediated vasodilation(FMD)in type 2 diabetes patientswith hypertension.Methods Subjects who were receiving treatment with valsartan prior to registration wereswitched to candesartan 8 mg/day(VC group, n=21)whereas those who were receiving candesartanwere switched to valsartan 80 mg/day(CV group, n=19)for an observation periodlasting 3 months. Percent FMD, blood pressure, and HbA1c were examined at baseline and 3months after starting treatment.Results The two groups did not differ in terms of patients’baseline clinical characteristicsand laboratory data. At 3 months, there were no significant changes in blood pressure andHbA1c in both groups. In the VC group percent FMD significantly increased at 3 months(from 4.7% to 5.8%;p<0.001), while in the CV group it significantly decreased(from 4.7%to 4.3%;p<0.001). Moreover, percent FMD at 3 months in the VC group was significantlyhigher than that in the CV group(p<0.05).Conclusions This study indicates that suppression of progression of endothelial dysfunctionby different ARBs is not a class effect;candesartan is more effective against progressionof arterial sclerosis than valsartan.(Jpn Pharmacol Ther 2009;37:757−62)KEY WORDS Flow−mediated vasodilation(FMD), Candesartan, Valsartan, Vascular endothelialdysfunction, Arterial sclerosis
Data & Media loading...